Phase III Confirmatory Trial to Confirm the Anti-anginal Effect of Dantonic (T89) in Patients With Chronic Stable Angina.

Trial Profile

Phase III Confirmatory Trial to Confirm the Anti-anginal Effect of Dantonic (T89) in Patients With Chronic Stable Angina.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs T 89 (Primary)
  • Indications Angina pectoris
  • Focus Therapeutic Use
  • Acronyms CAESA
  • Sponsors Tasly Pharmaceuticals, Inc.
  • Most Recent Events

    • 07 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 04 Jul 2016 Planned End Date changed from 1 Jun 2017 to 1 Jul 2016.
    • 04 Jul 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top